Lupus drug combo tested in tiny trial – but study halted early
NCT ID NCT05306873
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested the drugs mycophenolate mofetil (CellCept) alone or with voclosporin in 12 people with lupus. The goal was to see if these treatments work better in certain patient groups. However, the study was terminated early, so the results are very limited.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Mycophenolate mofetil (CellCept) and voclosporin
What this could lead to
If successful, this could point toward better ways to match lupus treatments to specific patient types, improving disease control.
What could go wrong
This was a very small, early-phase trial that was terminated early, so results are limited. It is unclear if the drugs will work better than existing options.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Columbia University Medical Center: Department of Medicine, Division of Rheumatology
New York, New York, 10032, United States
-
Emory University School of Medicine: Division of Rheumatology
Atlanta, Georgia, 30307, United States
-
Feinstein Institute for Medical Research: Center for Autoimmune and Musculoskeletal Diseases
Manhasset, New York, 11030, United States
-
Massachusetts General Hospital: Rheumatology, Allergy and Immunology, Center for Immunology and Inflammatory Diseases
Boston, Massachusetts, 02114, United States
-
Oklahoma Medical Research Foundation: Arthritis and Clinical Immunology Research Program
Oklahoma City, Oklahoma, 73104, United States
-
PennState Health Milton S. Hershey Medical Center: Division of Rheumatology
Hershey, Pennsylvania, 17033, United States
-
Piedmont Healthcare: Rheumatology Atlanta
Atlanta, Georgia, 30318, United States
-
UCLA Medical Center: Division of Rheumatology
Los Angeles, California, 90095, United States
-
University of North Carolina at Chapel Hill; Thurston Arthritis Research Center: Division of Rheumatology, Allergy, and Immunology
Chapel Hill, North Carolina, 27599, United States
-
Yale University School of Medicine: Rheumatology, Allergy & Immunology
New Haven, Connecticut, 06519, United States